Navigation Links
Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
Date:8/8/2008

eveloping and commercializing products targeting the extracellular matrix for the drug delivery, metabolism, oncology and dermatology markets. The company's portfolio of products and product candidates is based on intellectual property covering the family of human enzymes known as hyaluronidases. The company's Enhanze(TM) Technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. Its key partnerships are with Roche to apply Enhanze Technology to Roche's biological therapeutic compounds for up to 13 targets and with Baxter to apply Enhanze Technology to Baxter's biological therapeutic compound, GAMMAGARD LIQUID 10%. In addition, the company has received FDA approval for two products: Cumulase(R), for use in in-vitro fertilization, and HYLENEX, for use as an adjuvant to increase the absorption and dispersion of other injected drugs and fluids. HYLENEX is partnered with Baxter International Inc. The Company also has a number of different enzymes in its portfolio that are targeting significant areas of unmet need.

Safe Harbor Statement

In addition to historical information, the statements set forth above include forward-looking statements (including, without limitation, statements relating to an insulin product and conclusions and implications drawn from clinical and pre-clinical trial data) that involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are also identified through use of the words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including regulatory approval requirements and competitive conditions. These and other
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Halozyme Therapeutics to Present at the Jefferies 2nd Annual Healthcare Conference
2. Halozyme Therapeutics Reports 2008 First Quarter Financial Results
3. Halozyme Therapeutics to Hold Pipeline Update Conference Call on May 9
4. Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results
5. Halozyme Therapeutics Presents Favorable New Safety and Pharmacokinetic Data on rHuPH20 Enzyme Produced Via New Manufacturing Process at European Federation for Pharmaceutical Sciences
6. Halozyme Therapeutics to Hold Pipeline Update Conference Call on March 14
7. Halozyme Therapeutics to Present at the BIO CEO and Investor Conference and the Roth Growth Stock Conference
8. Halozyme Therapeutics Amends Stockholder Rights Plan
9. Halozyme Therapeutics Reports 2007 Third Quarter Financial Results
10. Halozyme Therapeutics to Present at UBS 2007 Global Life Sciences Conference
11. Baxter and Halozyme Announce Collaboration for Development of Subcutaneous GAMMAGARD LIQUID(TM) Administration Using Enhanze(TM) Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 2014   Cypher Genomics, Inc., the ... Adam Simpson as president and chief ... comprehensive annotation and interpretation of individual human genomes ... "Cypher,s technology has the potential to play a ... accuracy, optimizing therapeutic approaches and reducing adverse drug ...
(Date:7/23/2014)... Lyfebulb, the International Pemphigus Pemphigoid Foundation ... OMX First North Premier, Stockholm ... collaboration to increase awareness of unmet needs in ... attended by more than sixty patients, physicians, scientists ... and wellness company dedicated to serving the needs ...
(Date:7/23/2014)... made great strides in saving China,s endangered national treasure, ... 65 giant panda reserves that have been established and ... 1596 pandas remain in the wild. , Breeding ... the panda by improving genetic diversity, avoid inbreeding and ... are these high-profile programs doing so far? , In ...
(Date:7/23/2014)... July 23, 2014 /PRNewswire-iReach/ -- Think Drinks are a ... the long term. They are the first functional focus ... energy as an alternative to the temporary fix associated ... Indiegogo on July 29, 2014, with hopes to raise ... Photo - http://photos.prnewswire.com/prnh/20140723/129697 ...
Breaking Biology Technology:Cypher Genomics Announces the Appointment of Adam Simpson as President and COO to Advance Transformative Genome Interpretation Technology 2Cypher Genomics Announces the Appointment of Adam Simpson as President and COO to Advance Transformative Genome Interpretation Technology 3Innovative Collaboration To Increase Awareness Of Bullous Pemphigoid, A Rare Autoimmune Disease Of The Skin 2Innovative Collaboration To Increase Awareness Of Bullous Pemphigoid, A Rare Autoimmune Disease Of The Skin 3Innovative Collaboration To Increase Awareness Of Bullous Pemphigoid, A Rare Autoimmune Disease Of The Skin 4Innovative Collaboration To Increase Awareness Of Bullous Pemphigoid, A Rare Autoimmune Disease Of The Skin 5truBrain Neuroscientists To Launch More Effective, Healthier Alternative To Energy Drinks On Indiegogo 2
... SETAUKET, N.Y., May 25, 2011 John S. Kovach, ... Biotechnology Holdings, Inc. (LIXT.PK), announces the appointment of  Robert ... of Directors. Dr. Royds is Chair of ... a leading clinical research organization, which he founded in ...
... a Phase 2 multicenter, randomized, double-blind, proof-of-concept and ... 136) improved signs and symptoms of rheumatoid arthritis ... with methotrexate (MTX).  Findings from Part A of ... League Against Rheumatism (EULAR) Congress showed that a ...
... May 25, 2011 Watson Pharmaceuticals, Inc. (NYSE: ... today jointly announced that Watson has acquired the ... for EUR 400 million ($562 million) in cash ... the acquisition, Watson gains a leading generic product ...
Cached Biology Technology:Lixte Biotechnology Holdings Announces New Appointment to Board of Directors 2Lixte Biotechnology Holdings Announces New Appointment to Board of Directors 3Interleukin-6 Inhibitor Sirukumab (CNTO 136) Phase 2 Data Show Promise in the Treatment of Active Rheumatoid Arthritis 2Interleukin-6 Inhibitor Sirukumab (CNTO 136) Phase 2 Data Show Promise in the Treatment of Active Rheumatoid Arthritis 3Interleukin-6 Inhibitor Sirukumab (CNTO 136) Phase 2 Data Show Promise in the Treatment of Active Rheumatoid Arthritis 4Watson Acquires Specifar Pharmaceuticals 2Watson Acquires Specifar Pharmaceuticals 3Watson Acquires Specifar Pharmaceuticals 4Watson Acquires Specifar Pharmaceuticals 5Watson Acquires Specifar Pharmaceuticals 6
(Date:7/24/2014)... , July 24, 2014 NXT-ID, Inc., (NXTD: OTCQB) a ... announces its next generation smart wallet, Wocket™, was recently the topic ... Finley interviewed Gino Pereira , CEO of ... minutes. Mr. Gino Pereira ... full of credit cards and walks host Anita ...
(Date:7/23/2014)... -- Pfenex Inc. (NYSE MKT: PFNX) today announced the pricing ... common stock at a price to the public of $6.00 ... 30-day option to purchase up to 1,250,000 additional shares of ... are expected to begin trading on the NYSE MKT on ... William Blair & Company, L.L.C. and JMP Securities LLC ...
(Date:7/23/2014)... or neglected early in life are at risk ... In a new study, scientists have found that ... has implications for children,s long-term development. Previous studies ... and genetics interacted with that child,s experiences in ... In the new study, researchers were able to ...
Breaking Biology News(10 mins):Boomer Times Gets to Know NXT-ID's Next Generation Wocket Smart Wallet; Practical, Secure and Easy to Use 2Boomer Times Gets to Know NXT-ID's Next Generation Wocket Smart Wallet; Practical, Secure and Easy to Use 3Boomer Times Gets to Know NXT-ID's Next Generation Wocket Smart Wallet; Practical, Secure and Easy to Use 4Pfenex Inc. Announces Pricing Of Initial Public Offering 2Stress tied to change in children's gene expression related to emotion regulation, physical health 2Stress tied to change in children's gene expression related to emotion regulation, physical health 3
... -- An Illinois research team has succeeded in ... that simultaneously reduces atmospheric carbon dioxide and produces ... engineering professor Paul Kenis and his research group ... startup company, to produce a catalyst that improves ...
... New Rochelle, NY, October 6, 2011Measurable changes in brain ... consequence of virus-induced injury during the early stages of ... implications in disease prognosis are detailed in an article ... Connectivity , a bimonthly peer-reviewed journal published by ...
... new research program funded by the National Institutes of ... has on human health. Led by NIH,s National Institute ... the risk factors that make people more vulnerable to ... such as air pollution and toxic chemicals; and the ...
Cached Biology News:Ionic liquid catalyst helps turn emissions into fuel 2Changes in brain function in early HIV infection: A reliable indicator of disease prognosis? 2NIH launches research program to explore health effects from climate change 2NIH launches research program to explore health effects from climate change 3
... Synaptogyrin 2 ( Abpromise ... Antigen: Synthetic ... sequence amino acids 42-57 of ... Entrez Gene ID: ...
Rabbit polyclonal to SMURF 2 ( Abpromise for all tested applications). Antigen: A KLH conjugated synthetic peptide (10-30 aa in length) at the N-term of first 50 aa of human SMURF 2. Entrez G...
Rabbit polyclonal antibody to NCOA2 [Agarose Immobilized]...
Rabbit anti Mouse ZIC2 Preservative: NaN3...
Biology Products: